About-cancer / lapaʻau / clinical-hoʻokolohua / maʻi / anal-cancer / lapaʻau
Hana i nā hoʻokolohua lapaʻau no ka maʻi ʻaʻai anal
ʻO nā hoʻokolohua hoʻokolohua kahi noiʻi noiʻi e pili ana i ka poʻe. ʻO nā hoʻokolohua hoʻokolohua ma kēia papa inoa no ka mālama ʻana i ka maʻi ʻaʻai anal. Kākoʻo ʻia nā hoʻokolohua āpau ma ka papa inoa e NCI.
ʻO ka ʻike pili o NCI e pili ana i nā hoʻokolohua hoʻokolohua e wehewehe i nā ʻano a me nā pae o nā hoʻokolohua a pehea e lawe ai. Nānā nā hoʻāʻo hoʻokolohua i nā ala hou e pale ai, ʻike ai, a mālama ai paha i ka maʻi. E makemake paha ʻoe e noʻonoʻo e pili ana i ka lawe ʻana i ka hoʻokolokolo hoʻokolohua. E kamaʻilio me kāu kauka no ke kōkua i ka hoʻoholo ʻana inā kūpono kekahi iā ʻoe.
Nā hoʻāʻo 1-23 o 23
ʻO Nivolumab ma hope o ka hoʻohui ʻia ʻana o ka pono maʻamau i ka mālama ʻana i nā mea maʻi me ke kūlana kiʻekiʻe kiʻekiʻe II-IIIB ʻAe ʻAkā
Ke nānā nei kēia mahele II i ka hoʻokolohua hoʻokolohua hoʻokolohua pehea ka maikaʻi o ka nivolumab ma hope o ka hoʻoliʻiliʻi modality therapy i ka mālama ʻana i nā mea maʻi me ka maʻi maʻi maʻi maʻi maʻi II-IIIB kiʻekiʻe. Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a ke hoʻopilikia paha i ka hiki i nā pūpū tumora ke ulu a pālahalaha.
Kahi: 744 mau wahi
ʻO Nivolumab me ka ʻole o Ipilimumab i ka mālama ʻana i nā mea maʻi me ka maʻi kanal anal canastactory metastatic
Ke aʻo nei kēia mahele II i ka maikaʻi o ka nivolumab me a i ʻole me ka ʻole o ka ipilimumab e hana ai i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai anal i pane ʻole i ka lāʻau ma mua (refractory) a ua hoʻolaha ʻia i nā wahi ʻē aʻe o ke kino (metastatic). Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab a me ka ipilimumab, ke kōkua i ka ʻōnaehana pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora.
Kahi: 42 mau wahi
ʻO Nivolumab a me Ipilimumab i ka mālama ʻana i nā mea maʻi me ka HIV Associated Relapsed a i ʻole Refractory Classical Hodgkin Lymphoma a i ʻole Tumors paʻa paʻa i Metastatic a i ʻole hiki ke hemo ʻia e ka ʻoki kino.
Ke nānā nei kēia mahele hoʻokolohua i nā hopena a me ka hopena maikaʻi loa o ka nivolumab ke hāʻawi ʻia me ipilimumab i ka mālama ʻana i nā mea maʻi me ka maʻi pale maʻi (HIV) e pili ana i ka lymphoma Hodgkin kahiko i hoʻi mai ma hope o kahi manawa o ka hoʻomaikaʻi a pane ʻole paha i ka lapaʻau. ua pālahalaha aku i nā wahi ʻē aʻe o ke kino a i ʻole hiki ʻole ke wehe ʻia e ke ʻoki. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ipilimumab a me nivolumab, ke kōkua i ke kino o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūhaka tumo. ʻO Ipilimumab kahi maʻi ʻino e kūʻē i kahi mole i kapa ʻia ʻo cytotoxic T-lymphocyte antigen 4 (CTLA-4). Mālama ʻo CTLA-4 i kahi ʻāpana o kāu ʻōnaehana pale pale ma ka hoʻopau ʻana iā ia. ʻO Nivolumab kahi ʻano antibody i kikoʻī no ka make pūnaewele hoʻonaninani kanaka 1 (PD-1), he protein i kuleana no ka luku ʻia ʻana o nā hunaola pale. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka ipilimumab me ka nivolumab i ka mālama ʻana i nā mea maʻi me ka maʻi HIV e pili ana i ka lymphoma Hodgkin a i ʻole nā tumors paʻa e hoʻohālikelike ʻia me ka ipilimumab me ka nivolumab wale nō.
Kahi: 28 mau wahi
Ke aʻo ʻana o XmAb®20717 i nā kumuhana me nā Tumors Solid Advanced i wae ʻia
ʻO kēia kahi pae 1, nā mahele lāʻau he nui, e piʻi nei i ka hoʻonui ʻana o ka lāʻau e wehewehe ai i ka MTD / RD a me ka regimen o XmAb20717, e wehewehe i ka palekana a me ka hoʻomanawanui ʻana, e loiloi iā PK a me ka immunogenicity, a me ka loiloi mua i ka hana anti-tumor o XmAb20717 i nā kumuhana me ke koho nā tumors paʻa holomua.
Kahi: 15 mau wahi
ʻO kahi noiʻi Immuno-therapy e noiʻi e noiʻi i ka palekana a me ka pono o Nivolumab, a me Nivolumab Combapy Therapy i nā Tumors e pili ana i ka Virus.
ʻO ke kumu o kēia noi ʻana e nānā i ka palekana a me ka pono o ka nivolumab, a me ka nivolumab hui pū ʻia, e mālama ai i nā mea maʻi i loaʻa i nā tumor e pili ana i ka maʻi virus. Ua ʻike ʻia kekahi mau mea ʻino e pāʻani i ka hana a me ka ulu ʻana o ka tumo. E nānā ana kēia noiʻi i nā hopena o nā lāʻau i hoʻopaʻa ʻia, i nā mea maʻi i loaʻa nā ʻano tumors penei: - Ka maʻi ʻaʻai canal anal-ʻAʻole kākau inoa hou i kēia ʻano tumo - maʻi ʻaʻai cervical - Epstein Barr Virus (EBV) maʻi ʻōpū gastric maikaʻi-ʻAʻole kākau inoa hou i kēia. ʻano tumo - Ka maʻi ʻaʻai ʻo Merkel Cell - Ka maʻi ʻaʻai Penile-ʻAʻole kākau inoa hou i kēia ʻano tumo - Wela a me nā maʻi ʻino ʻele - ʻAʻole kākau inoa hou i kēia ʻano tumo - Ka maʻi ʻaʻai Nasopharyngeal - ʻAʻole kākau inoa hou i kēia ʻano tumo
Kahi: 10 mau wahi
Ke aʻo ʻana o Pembrolizumab (MK-3475) i nā mea komo me nā Tumors Pae holomua (MK-3475-158 / KEYNOTE-158)
I kēia noi ʻana, e mālama ʻia nā mea komo me nā ʻano nui o nā tumors paʻa mua (unresectable a me / a metastatic paha) i holomua ma ke kūlana o ka mālama mālama me ka pembrolizumab.
Kahi: 8 mau wahi
ʻO Brachytherapy Dose High-Dose-Rate a me Chemotherapy i ka mālama ʻana i nā mea maʻi me kahi kūloko kūloko a i ʻole Residual Rectal a i ʻole Ka maʻi ʻaʻai anal e pili ana i ka hoʻokele ʻole hana
Ke nānā nei kēia maʻa wau i nā hopena a me ka mahele lāʻau ʻoi loa o ka brachytherapy kiʻekiʻe loa i ka wā e hāʻawi ʻia ai me chemotherapy i ka mālama ʻana i nā mea maʻi me ka maʻi kanesa rectal a anal paha i hoʻi mai a maikaʻi ʻole paha a ʻaʻole hiki ke mālama ʻia me ke ʻoki. ʻO Brachytherapy, i ʻike ʻia ma ke ʻano he radiation radiation, hoʻohana i nā mea radioactive i hoʻonoho pololei ʻia i loko a kokoke paha i kahi tumo e pepehi ai i nā hunaola tumora. Hoʻohana ka brachytherapy dosis-kiʻekiʻe (HDR) i ka mea radioactive e hāʻawi i kahi lāʻau radiation kiʻekiʻe i kahi manawa pōkole o ka manawa i ka tum tum. Hiki iā ia ke hoʻouna i kahi radiation liʻiliʻi i nā pūnaewele olakino kokoke a hōʻemi paha i ka hopena o nā hopena ʻaoʻao. ʻO nā lāʻau i hoʻohana ʻia i ka chemotherapy, e like me capecitabine a me fluorouracil, hana i nā ala like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, ma ka luku ʻana paha i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kāpae ʻana iā lākou mai ka hoʻolaha ʻana.
Kahi: 6 mau wahi
Pembrolizumab i ka mālama ʻana i nā mea maʻi me ka Metastatic a i ʻole ka maʻi maʻi kūloko holomua i hiki ʻole ke hemo ʻia e ke ʻoki kino.
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana ʻana o ka pembrolizumab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai anal i pāhola ʻia i nā wahi ʻē aʻe o ke kino a i ʻole ua pālahalaha ʻia mai kona kahua kumu o ka ulu ʻana i nā mea kokoke a i ʻole nā lymph node a ʻaʻole hiki ke hemo ʻia e ke ʻoki. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku.
Kahi: 5 mau wahi
ʻO ke ʻoki ʻana i ka mālama ʻana i nā mea maʻi me ka Canal Anal Early Stage a i ʻole Perianal Cancer a me ka Positive HIV
Ke aʻo nei kēia pae II i ka ʻoki ʻana i ka mālama ʻana i nā mea maʻi me ka canal anal a i ʻole ka maʻi ʻaʻai perianal i liʻiliʻi a ʻaʻole pālahalaha loa i loko o nā aʻa a me nā maʻi pale maʻi (HIV) maikaʻi. ʻO kahi ʻoki kūloko paha kahi ʻoi aku ka palekana o ka mālama ʻana me nā hopena ʻē aʻe ma mua o ke kīpē nui a i ʻole radiation a me chemotherapy.
Kahi: 5 mau wahi
He hoʻāʻo e ʻimi a noiʻi i kahi hana palekana o kahi mea hou (BI 754091) no nā mea maʻi me nā tumors paʻa.
ʻO ka pahuhopu nui o ka ʻāpana hoʻonui-ʻāpana o ka hoʻokolokolo ka hoʻoholo ʻana i ka palekana a me ke ahonui, a me ka hoʻoholo ʻana i ka Dose Tolerated Maximum and / or the Recommended Phase 2 Dose (RP2D) o BI 754091 ma ke kumu o nā mea maʻi me ka palena lāʻau. nā mea ʻona (DLT) i nā mea maʻi me nā maʻi ʻino paʻa i wae ʻia i wae ʻia. E loiloi ʻia ka palekana a me ka hoʻomanawanui ʻana ma o ka nānā ʻana i ka hanana o nā hanana maikaʻi ʻole (AEs), nā AE koʻikoʻi (SAE), a me nā ʻokoʻa pono o ke keʻena hoʻokolohua, a me nā loli i nā hōʻailona koʻikoʻi. ʻO nā pahuhopu kiʻekiʻe ka hoʻoholo ʻana o ka ʻikepili PK o BI 754091 ma hope o hoʻokahi a me nā kau o BI 754091, a me ka loiloi mua o ka hana antitumour. I ka mahele hoʻonui? Ana o ka hoʻokolokolo, ʻo nā pahuhopu nui e nānā hou i ka palekana, ka pono, ka ʻike PK,
Kahi: 3 mau wahi
ʻO Radiosurgery Stereotactic i ka mālama ʻana i nā mea maʻi me ka maʻi Oligometastatic
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana ʻana o ka radiosurgery stereotactic i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai i pāhola ʻia i 5 a i ʻole nā wahi liʻiliʻi paha o ke kino a pili iā 3 a ʻoi aku paha nā ʻāpana (maʻi oligometastatic). ʻO ka radiosurgery Stereotactic, i ʻike ʻia ʻo stereotactic body radiation therapy, kahi radiation radiation kūikawā e hāʻawi i kahi hoʻokahi, kiʻekiʻe o ka radiation i pololei i ka puʻupuʻu a make paha i nā hunaola tumole a hoʻoliʻiliʻi liʻiliʻi i kaʻiʻo maʻamau.
Kahi: 3 mau wahi
Ke aʻo ʻana o INCMGA00012 i ka Squamous Carcinoma o ka Canal Anal ma hope o ka Chemotherapy Platinum-Base (POD1UM-202)
ʻO ke kumu o kēia noi ʻana e nānā i ka pono o INCMGA00012 i nā mea komo me ka carcinoma squamous squamous holomua a me ka metastatic o ka canal anal (SCAC) i holomua ma hope o ka chemotherapy kahua platinum.
Kahi: 4 mau wahi
ʻO Artesucky i ka mālama ʻana i nā mea maʻi me ka Neoplasia Intraepithelial Anal kiʻekiʻe
ʻO kēia pae aʻu e hoʻāʻo nei e hoʻopaʻa i nā ʻaoʻao a me ka mahele lāʻau ʻoi loa i ka mālama ʻana i nā mea maʻi me ka neoplasia intraepithelial anal kiʻekiʻe. ʻO nā neoplasia intraepithelial anal he mau cell precancerous e hiki a lilo paha i kanesa i ka wā e hiki mai ana. ʻO ka hapa nui o nā hoʻololi e alakaʻi i ka maʻi ʻaʻai e hoʻokumu ʻia e ka papillomavirus kanaka (HPV). Pepehi paha ʻo Artesucky i nā hunaola i hoʻopili ʻia me HPV.
Kahi: 2 mau wahi
Ke aʻo ʻana iā LY3434172, kahi PD-1 a me PD-L1 Bispecific Antibody, ma Advanced Cancer
ʻO ke kumu nui o kēia noi ʻana e loiloi i ka palekana a me ka hoʻomanawanui ʻana i ka lāʻau lapaʻau LY3434172, kahi maʻi PD-1 / PD-L1 bispecific antibody, i nā mea komo me nā tumors paʻa mua.
Kahi: MD Anderson Cancer Center, Houston, Texas
SL-279252 (PD1-Fc-OX40L) i nā kumuhana me nā Tumors Solid Advanced a i ʻole Lymphomas.
ʻO kēia kahi pae 1 mua i loko o ke kanaka, ka lepili hāmama, ke kikowaena waena, ka piʻi ʻana o ka lāʻau a me ka hoʻonui ʻana o ka lāʻau e loiloi i ka palekana, ka hoʻomanawanui, PK, ka hana anti-tumor a me nā hopena pharmododynamic o SL-279252 i nā kumuhana me nā tumors paʻa mua a i ʻole nā lymphomas. .
Kahi: MD Anderson Cancer Center, Houston, Texas
LET-IMPT a me Chemotherapy Maʻamau i ka mālama ʻana i nā mea maʻi me ka pae hou i ʻike ʻia me ka I-III Anal Canal Squamous Cell Cancer
Ke aʻo nei kēia mahele II i nā hopena o ka LET-IMPT a me ka chemotherapy maʻamau, a me ka maikaʻi o kā lākou hana ʻana i ka mālama ʻana i nā mea maʻi me ka maʻi I-III anal canal squamous cell cancer. ʻO LET-IMPT kahi ʻano o ka radiation therapy e hoʻohana i nā proton "beamlets" kiʻekiʻe e "pena" i ka hopena radiation i loko o ka pahuhopu a hiki ke kōkua i ka luku ʻana i nā pūpū tumora a me ka hōʻemi ʻana i nā tumors. ʻOi aku ka maikaʻi o ka hāʻawi ʻana iā LET-IMPT a me ka chemotherapy maʻamau i ka mālama ʻana i nā mea maʻi me ka maʻi maʻi maʻi maʻi canal squalous cell.
Kahi: MD Anderson Cancer Center, Houston, Texas
VGX-3100 a me ka uila ma ka mālama ʻana i nā mea maʻi me nā leona anal kūlana kiʻekiʻe HIV
Ke aʻo nei kēia mahele II i ke ʻano o ka maikaʻi o ke kanaka papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids vaccine VGX-3100 (VGX-3100) a me ka hana electroporation i ka mālama ʻana i nā mea maʻi me ka maʻi pale maʻi kanaka (HIV) - nā lesions anal kiʻekiʻe. Hiki i nā lāʻau āpau i hana ʻia mai DNA ke kōkua i ke kino e kūkulu i kahi pane pale pale ʻole e pepehi i nā hunaola tumora. Kōkua ka uila i nā pores i loko o nā hunaola o kou kino e lawe i ka lāʻau e hoʻoikaika i ka pane o kāu ʻōnaehana pale. ʻOi aku ka maikaʻi o ka hāʻawi ʻana iā VGX-3100 a me ka electroporation i ka mālama ʻana i nā mea maʻi me nā leona anal kiʻekiʻe.
Kahi: 2 mau wahi
ʻO DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Huahana Hoʻoikaika INO-3112 a me Durvalumab i ka mālama ʻana i nā mea maʻi me nā mea hōʻeha a me ka Metastatic Human Papillomavirus Associated Cancers.
Ke aʻo nei kēia mahele II i ka maikaʻi o ka deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids vaccine therapeutic INO-3112 a me ka durvalumab hana i ka mālama ʻana i nā mea maʻi me nā maʻi maʻi pili papillomavirus kanaka i hoʻi mai a pāhola ʻia i nā poʻe ʻē aʻe. nā wahi i ke kino. Hiki i nā maʻi āpau i hana ʻia mai kahi maʻi hoʻomaikaʻi i hoʻohuli ʻia ke ʻenekini ke kōkua i ke kino e kūkulu i kahi pane pale pale e pono ai e luku i nā pūpū tumora. Hiki i ka Immunotherapy me nā ʻōpala monoclonal, e like me durvalumab, ke kōkua i ke kino pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūhaka tumo. ʻO ka hāʻawi ʻana iā DNA plasmid-encoding interleukin-12 / HPV DNA plasmids therapeutic vaccine INO-3112 a me durvalumab i hiki ke hana ʻoi aku ka maikaʻi i ka mālama ʻana i nā mea maʻi me nā maʻi ʻino pili papillomavirus kanaka.
Kahi: MD Anderson Cancer Center, Houston, Texas
M7824 i nā kumuhana me nā HPign Associated Malignancies
ʻIke: Ma ʻAmelika Hui Pū ʻIa, i kēlā me kēia makahiki aia ma mua o 30,000 mau hihia o nā maʻi maʻi pili papillomavirus kanaka (HPV) e pili ana. ʻAʻole hiki ke hoʻōla pinepine ʻia kekahi o kēia mau maʻi maʻi a ʻaʻole hoʻomaikaʻi ʻia e nā ʻano maʻamau maʻamau. Makemake nā kānaka noiʻi inā he M7824 lāʻau lapaʻau hou, kahi e mākaukau a ālai i ke ala e pale ai i ka ʻōnaehana pale pale mai ka hakakā pono ʻana i ka maʻi ʻaʻai hiki ke hoʻoliʻiliʻi i nā tumors i ka poʻe me kekahi mau maʻi maʻi HPV. Nives Pahuhopu: E ʻike inā hana ka lāʻau M7824 i nā tumors e mimiki. ʻO nā kūpono: ʻO nā mākua nona nā makahiki 18 a ʻoi paha i loaʻa i ka maʻi ʻaʻai e pili ana i ka maʻi HPV. Hoʻolālā: E paʻi ʻia nā mea komo me ka mōʻaukala olakino a me ka hoʻāʻo kino. E nānā lākou i kā lākou hōʻailona a pehea e hana ai i nā hana maʻamau. E nānā lākou i ke kino. Hāʻawi lākou i ke koko a me nā mimi. E loaʻa iā lākou kahi laʻana o kā lākou kele tuma i lawe ʻia inā loaʻa ʻole kekahi. E loaʻa ka electrocardiogram i nā mea komo e loiloi i ko lākou puʻuwai. A laila e loaʻa iā lākou ka lāʻau hoʻāʻo ma o kahi paipu lahilahi i ka aa lima. E loaʻa i ka poʻe komo ka lāʻau i kēlā me kēia 2 pule no 26 mau manawa (1 makahiki). ʻO kēia papa 1. Ma hope o ka papa, e kiaʻi ʻia ka poʻe komo akā ʻaʻole lawe i ka lāʻau noiʻi. Inā hele a hewa ko lākou kūlana, e hoʻomaka lākou i kahi papa ʻē aʻe me ka lāʻau. Hiki ke hana hou i kēia hana i nā manawa i makemake ʻia. E kū ke kuʻina inā loaʻa nā hopena maikaʻi ʻole o ka mea i komo a i ʻole kū ka lāʻau i ka hana. Ma loko o ke aʻo ʻana, e hana hou nā mea komo i kekahi a i ʻole nā hōʻike loiloi āpau. Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... A laila e loaʻa iā lākou ka lāʻau hoʻāʻo ma o kahi paipu lahilahi i ka aa lima. E loaʻa i ka poʻe komo ka lāʻau i kēlā me kēia 2 pule no 26 mau manawa (1 makahiki). ʻO kēia papa 1. Ma hope o ka papa, e kiaʻi ʻia ka poʻe komo akā ʻaʻole lawe i ka lāʻau noiʻi. Inā hele a hewa ko lākou kūlana, e hoʻomaka lākou i kahi papa ʻē aʻe me ka lāʻau. Hiki ke hana hou i kēia hana i nā manawa i makemake ʻia. E kū ke kuʻina inā loaʻa nā hopena maikaʻi ʻole o ka mea i komo a i ʻole kū ka lāʻau i ka hana. Ma loko o ke aʻo ʻana, e hana hou nā mea komo i kekahi a i ʻole nā hōʻike loiloi āpau. Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... A laila e loaʻa iā lākou ka lāʻau hoʻāʻo ma o kahi paipu lahilahi i ka aa lima. E loaʻa i ka poʻe komo ka lāʻau i kēlā me kēia 2 pule no 26 mau manawa (1 makahiki). ʻO kēia papa 1. Ma hope o ka papa, e kiaʻi ʻia ka poʻe komo akā ʻaʻole lawe i ka lāʻau noiʻi. Inā hele a hewa ko lākou kūlana, e hoʻomaka lākou i kahi papa ʻē aʻe me ka lāʻau. Hiki ke hana hou i kēia hana i nā manawa i makemake ʻia. E kū ke kuʻina inā loaʻa nā hopena maikaʻi ʻole o ka mea i komo a i ʻole kū ka lāʻau i ka hana. Ma loko o ke aʻo ʻana, e hana hou nā mea komo i kekahi a i ʻole nā hōʻike loiloi āpau. Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... e nānā ʻia nā mea komo akā ʻaʻole lawe i ka lāʻau aʻo. Inā hele a hewa ko lākou kūlana, e hoʻomaka lākou i kahi papa ʻē aʻe me ka lāʻau. Hiki ke hana hou i kēia hana i nā manawa i makemake ʻia. E kū ke kuʻina inā loaʻa nā hopena maikaʻi ʻole o ka mea i komo a i ʻole kū ka lāʻau i ka hana. Ma loko o ke aʻo ʻana, e hana hou nā mea komo i kekahi a i ʻole nā hōʻike loiloi āpau. Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... e nānā ʻia nā mea komo akā ʻaʻole lawe i ka lāʻau aʻo. Inā hele a hewa ko lākou kūlana, e hoʻomaka lākou i kahi papa ʻē aʻe me ka lāʻau. Hiki ke hana hou i kēia hana i nā manawa i makemake ʻia. E kū ke kuʻina inā loaʻa nā hopena maikaʻi ʻole o ka mea i komo a i ʻole kū ka lāʻau i ka hana. Ma loko o ke aʻo ʻana, e hana hou nā mea komo i kekahi a i ʻole nā hōʻike loiloi āpau. Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ... Ma hope o ka pau ʻana o ka lawe ʻana i ka lāʻau e ka poʻe komo, e kipa hou lākou a hana hou i kekahi mau hōʻike loiloi. E kāhea aku lākou i nā kelepona kūmau. ...
Kahi: National Institutes of Health Clinical Center, Bethesda, Maryland
MnSOD Mimetic BMX-001 i ka mālama ʻana i nā mea maʻi me ka maʻi kanesa maʻi e mālama ana i ka radiation radiation a me ka Chemotherapy
Ke aʻo nei kēia mahele hoʻokolohua i ka mahele lāʻau ʻoi loa o MnSOD mimetic BMX-001 e hōʻemi i nā hopena i nā maʻi me ka maʻi ʻaʻai anal e mālama ʻia ana i ka radiation radiation a me ka chemotherapy. Hiki i nā lāʻau chemoprotective, e like me BMX-001, ke pale aku i nā hunaola maʻamau mai nā hopena ʻaoʻao o ka chemotherapy ʻoiai e hoʻonui ana i ka luku i ka tumo.
Kahi: University of Nebraska Medical Center, Omaha, Nebraska
ʻO Atezolizumab a me Bevacizumab i ka mālama ʻana i nā mea maʻi me nā tumors paʻa ʻole
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana atezolizumab a me ka bevacizumab i ka mālama ʻana i nā mea maʻi me nā tumors paʻa paʻa. Hiki i ka Immunotherapy me nā antibodies monoclonal, e like me atezolizumab a me bevacizumab, ke kōkua i ke kino pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki ke ulu a pāhola nā pūhaka tumora.
Kahi: MD Anderson Cancer Center, Houston, Texas
ʻO Vaccine Therapy a me Cyclophosphamide i ka mālama ʻana i nā mea maʻi me HLA-A * 02 Positive Relapsed, Refractory, a i ʻole Metastatic HPV16-e pili ana i ka Oropharyngeal, Cervical, a i ʻole ka maʻi ʻaʻai ʻāne.
Ke aʻo nei kēia kaʻina hana Ib / II i nā hopena a me ka mahele lāʻau maikaʻi loa o HPV16-E711-19 vaccine nanomer DPX-E7 a ʻike i ke ʻano o ka maikaʻi ke hāʻawi ʻia me cyclophosphamide i ka mālama ʻana i nā mea maʻi me HLA-A * 02 maikaʻi, papillomavirus kanaka 16 ( HPV16) -ʻO ka oropharyngeal pili, cervix, a i ʻole ka maʻi ʻaʻai anal i hoʻi mai, ʻaʻole pane i ka lāʻau, a ua pāhola paha i nā ʻāpana ʻē aʻe o ke kino. Hiki i nā maʻi āpau i hana ʻia mai kahi maʻi hoʻomaikaʻi i hoʻohuli ʻia ke ʻenekini ke kōkua i ke kino e kūkulu i kahi pane pale pale e pono ai e luku i nā pūpū tumora. ʻO nā lāʻau i hoʻohana ʻia i ka chemotherapy, e like me cyclophosphamide, hana i nā ʻano like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, a i ʻole ma ka luku ʻana i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kū ʻana iā lākou mai ka hoʻolaha ʻana ʻO ka hāʻawi ʻana i ka lāʻau ākea HPV16-E711-19 nanomer DPX-E7 me ka cyclophosphamide e ʻoi aku ka maikaʻi ma ka mālama ʻana i nā mea maʻi me ka oropharyngeal e pili ana iā HPV16,
Kahi: Dana-Farber Cancer Institute, Boston, Massachusetts
ʻO Nivolumab a me Ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors liʻiliʻi
ʻO kēia pae II hoʻokolohua hoʻopaʻa haʻawina nivolumab a me ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors laha ʻole. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab a me ka ipilimumab, ke kōkua i ka ʻōnaehana pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora. Hoʻokomo kēia hoʻokolokolo i nā mea komo aku no kēia mau cohort e pili ana i ke ʻano: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A , and squamous cell carcinoma o ke poʻo a me ka ʻāʻī [SCCHN]) B) Adenocarcinoma a me nā ʻano like ʻole o ka puka ihu, sinus, a me nasopharynx (pani ʻia i ka accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03 / 20/2018) 3. ʻO nā tumors type gland salivary o ke poʻo a me ka ʻāʻī, lehelehe, esophagus, ʻōpū, trachea a me ka akemāmā, ka umauma a me nā wahi ʻē aʻe (pani ʻia i ka accrual) 4. Ka maʻi kanesa ʻole o ka gastrointestinal (GI) ʻāpana 5. Adenocarcinoma me nā ʻano o ka ʻōpū liʻiliʻi (pani ʻia i ka ʻohi 05/10/2018) 6. ʻO ka maʻi kanesa liʻiliʻi me nā ʻano like ʻole o ke kahawai GI (ʻōpū ʻōpū ʻōpū, kolona, ka pololei, pancreas) (pani ʻia i ka accrual 10/17/2018) 7. Fibromixoma a me ka adenocarcinoma mucous papa haʻahaʻa (pseudomixoma peritonei) o ka pākuʻi a me ka ovary (pani ʻia i ka accrual 03/20/2018) 8. Laʻi ʻole nā tumere pancreatic me ka acinar cell carcinoma, cystadenocarcinoma mucous a i ʻole cystadenocarcinoma serous. ʻAʻole kūpono ka pancreatic adenocarcinoma 9. Intrahepatic cholangiocarcinoma (pani ʻia i ka accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (pani ʻia i ka accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. Kapa ʻia kēia ʻano i kēia manawa he adenocarcinoma in situ, adenocarcinoma invasive minimally, lepidic predominant adenocarcinoma, a i ʻole invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian huikau tumor a me adenosarcoma (pani i ka accrual 03/30/2018) 14. Trophoblastic tumo: A) Choriocarcinoma (pani ʻia i ka accrual 04/15/2019) 15. ʻO ke kinetona cell transitional ʻē aʻe ma mua o ka puʻuwai, pelvis, ureter, a i ʻole bladder (pani ʻia i ka accrual 04 / 15/2019) 16. Pūnaewele tumora o nā ho'āʻo a me nā tumors germ extragonadal: Apocrine tumors / extramammary Paget's disease 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (pani ʻia i ka accrual) 45. E hoʻomaʻemaʻe i ka maʻi maʻi maʻi endometrial cancer 46. Clear cell maʻi ʻaʻai ovarian 47. maʻi Gestational trophoblastic (GTD) 48. Ka maʻi ʻaʻai Gallbladder 49. Ka maʻi liʻiliʻi liʻiliʻi o ka ovary, ʻano hypercalcemic 50. PD-L1 hoʻonui ʻia nā puʻupuʻu 51. Angiosarcoma 52. ʻO ka neuroendocrine carcinoma kiʻekiʻe (tumreatic neuroendocrine tum [PNET] pono e kākau inoa ʻia ma Cohort 22; pono e kākau inoa ʻia nā carrosomas neuroendocrine prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) Maʻemaʻe ka maʻi ʻaʻai maʻi hēhē 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Liʻiliʻi cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. Pono e kākau inoa ʻia ka neuroendocrine carcinoma kiʻekiʻe (Tumreatic neuroendocrine tum [PNET] i Cohort 22; pono e kākau inoa ʻia nā carrosomas neuroendocrine prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) Maʻemaʻe ka maʻi ʻaʻai maʻi hēhē 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Liʻiliʻi cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. Pono e kākau inoa ʻia ka neuroendocrine carcinoma kiʻekiʻe (Tumreatic neuroendocrine tum [PNET] i Cohort 22; pono e kākau inoa ʻia nā carrosomas neuroendocrine prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) Maʻemaʻe maʻi ʻaʻa maʻi ovarian 47. maʻi Gestational trophoblastic (GTD) 48. Ka maʻi ʻaʻai pākī 49. Ka maʻi liʻiliʻi liʻiliʻi o ka ovary, ʻano hypercalcemic 50. Hoʻonui nā PD-L1 i nā tumors 51. Angiosarcoma 52. ka neuroendocrine carcinoma kiʻekiʻe (tumreatic neuroendocrine tumor [PNET ] pono e kākau inoa ʻia ma Cohort 22; pono e kākau inoa ʻia nā neuroendocrine carcinomas prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) Maʻemaʻe maʻi ʻaʻa maʻi ovarian 47. maʻi Gestational trophoblastic (GTD) 48. Ka maʻi ʻaʻai pākī 49. Ka maʻi liʻiliʻi liʻiliʻi o ka ovary, ʻano hypercalcemic 50. Hoʻonui nā PD-L1 i nā tumors 51. Angiosarcoma 52. ka neuroendocrine carcinoma kiʻekiʻe (tumreatic neuroendocrine tumor [PNET ] pono e kākau inoa ʻia ma Cohort 22; pono e kākau inoa ʻia nā neuroendocrine carcinomas prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) pono e kākau inoa ʻia nā carrosomas neuroendocrine prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC) pono e kākau inoa ʻia nā carrosomas neuroendocrine prostatic i Cohort 53). ʻAʻole kūpono ʻia ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi 53. Lapaʻau-kū hou neuroendocrine maʻi ʻaʻai liʻiliʻi prostate (t-SCNC)
Kahi: 878 mau wahi
